Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications.

Mannitol (M) and deferoxamine (DFO) can each protect against myohemoglobinuric acute renal failure (MH-ARF). This study assessed M-DFO interactions during MH-ARF to help discern mechanisms of renal injury, and to define whether M + DFO exerts additive or synergistic antioxidant/cytoprotective effect...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

I whakaputaina i:	J Clin Invest
Kaituhi matua:	Zager, R A
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	American Society for Clinical Investigation 1992
Ngā marau:	Research Article
Urunga tuihono:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC329921/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1325995/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI115942
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!